title: Should Race-Genotype Interactions Be Considered in the Global Development of CYP2C19 Substrates? A Proposed Framework Using Physiologically Based Pharmacokinetic Modeling.
authors.affiliation: Takeda Pharmaceuticals International Company, Cambridge, MA, USA.
authors.forename: Chirag
authors.initials: C
authors.lastname: Patel
authors.affiliation: University of Tennessee Health Science Center, Memphis, TN, USA.
authors.forename: Chetan
authors.initials: C
authors.lastname: Rathi
authors.affiliation: Takeda Pharmaceuticals International Company, Cambridge, MA, USA.
authors.forename: Karthik
authors.initials: K
authors.lastname: Venkatakrishnan
mesh_terms: D065731:Cytochrome P-450 CYP2C19 / Q000235:genetics* / Q000378:metabolism; D065697:Cytochrome P-450 CYP2C19 Inducers / Q000378:metabolism / Q000494:pharmacology*; D065689:Cytochrome P-450 CYP2C19 Inhibitors / Q000378:metabolism / Q000494:pharmacology*; D055808:Drug Discovery / Q000379:methods / Q000639:trends; D005838:Genotype; D006801:Humans; D008954:Models, Biological; D044469:Racial Groups / Q000235:genetics*; D013379:Substrate Specificity / Q000187:drug effects / Q000502:physiology
chemical_list: D065697:Cytochrome P-450 CYP2C19 Inducers; D065689:Cytochrome P-450 CYP2C19 Inhibitors; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19
keywords: CYP2C19; PBPK; genetic polymorphism; genotype; physiologically based pharmacokinetic modeling; race